Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Protagonist Therapeutics, Inc. announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor antagonist JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis presented at World Congress of Dermatology in Singapore.